Media Contact:
Nancy Pecota
Chief Financial Officer
Assistant: Rita Mateo
Phone: 510-265-9370
E-mail: investor@aradigm.com
Latest News
Aradigm
to Present at the 10th Annual BIO Investor Forum on October 26
[20OCT11]
Aradigm
Presents Additional Analyses of the Clinical Results From ORBIT-1
and ORBIT-2 Trials of Inhaled Ciprofloxacin at the 2011 European
Respiratory Society (ERS) Annual Congress
[21SEP11]
Aradigm
to Present at Rodman & Renshaw Annual Global Investment Conference
[07SEP11]
Aradigm
Announces Second Quarter 2011 Financial Results
[09AUG11]
Aradigm
Announces Private Placement for $4.75 Million
[06JUL11]
Aradigm
Enters $8.5 Million Royalty Financing Agreement With PBS Capital
Management LLC
[22JUN11]
Aradigm
Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal
Ciprofloxacin
[16JUN11]
Aradigm
Receives FDA Orphan Drug Designation for Ciprofloxacin for Inhalation
in Bronchiectasis
[06JUN11]
Aradigm
Announces First Quarter 2011 Financial Results
[12MAY11]
Aradigm
to Present Additional ORBIT-2 Clinical Trial Results at Respiratory
Drug Delivery Europe 2011 Conference
[03MAY11]
Aradigm
Announces Fourth Quarter 2010 and Full Year Financial Results
[24MAR11]
Aradigm
Completes Enrollment in Phase 2b Study of Inhaled Ciprofloxacin
for the Management of Respiratory Infections in Bronchiectasis
[22MAR11]
Aradigm
to Present at ROTH Capital Partners 23rd Annual OC Growth Stock
Conference
[10MAR11]
Aradigm
to Present at the 13th Annual Biotechnology Industry Organization
(BIO) CEO & Investor Conference
[10FEB11]
SUMAVEL
DosePro Receives Marketing Approval in Germany and the United Kingdom
[11JAN11]
Aradigm
to Report Expanded Results from Successful Six-Month Phase 2b Bronchiectasis
Study at Biotech Showcase 2011
[06JAN11]
SUMAVEL
DosePro is Granted First European Approval
[07DEC10]
Aradigm
Announces Third Quarter 2010 Financial Results
[11NOV10]
Aradigm
Appoints Tamar Howson to Board of Directors
[04NOV10]
Aradigm
Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over
$733,000 for Inhaled Liposomal Ciprofloxacin Program
[02NOV10]
Aradigm
Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal
Ciprofloxacin
[20OCT10]
Aradigm
to Present at the 9th Annual BIO Investor Forum on )ctober 6
[04OCT10]
Aradigm
CEO Igor Gonda to Be Featured Guest Interview on StockGoodies.com
Radio on September 30
[30SEP10]
Aradigm
Announces Exercise of Warrants for Proceeds of Approximately $891,000
[23SEP10]
Aradigm
Closes Equity for Debt Transaction with Novo Nordisk A/S
[20SEP10]
Aradigm
Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal
Ciprofloxacin Formulations at the 2010 European Respiratory Society
(ERS) Annual Congress
[17SEP10]
Aradigm
Announces Second Quarter 2010 Financial Results
[12AUG10]
Aradigm
Announces Equity for Debt Transaction with Novo Nordisk
[02AUG10]
Aradigm
Announces Private Placement for $5 Million
[21JUN10]
Aradigm
Presents at the 2010 International Conference of the American Thoracic
Society
[17MAY10]
Aradigm
Announces First Quarter 2010 Financial Results
[13MAY10]
Aradigm
Receives FDA Clearance for Clinical Trial of Inhaled Liposomal Ciprofloxacin
in Pediatric Patients With Cystic Fibrosis
[05MAY10]
Aradigm
Completes Enrollment and Doses Last Patient in Long Term Phase 2
Study of a Novel Inhaled Ciprofloxacin Formulation for the Management
of Respiratory Infections in Bronchiectasis
[25MAR10]
Aradigm
Announces Fourth Quarter 2009 and Full Year Financial Results
[23MAR10]
Aradigm
Doses First Patient in Its Second Phase 2b Clinical Trial of Inhaled
Liposomal Ciprofloxacin in Bronchiectasis Patients
[23FEB10]
Aradigm
Receives $4 Million Milestone Payment Upon First Commercial Sale
of SUMAVEL* DosePro*
[04FEB10]
Aradigm
to Present at Biotech Showcase 2010 on January 12
[06JAN10]
Aradigm
to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
[10DEC09]
Aradigm
Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled
Ciprofloxacin Formulation for the Management of Respiratory Infections
in Bronchiectasis
[16NOV09]
Aradigm
Announces Third Quarter 2009 Financial Results
[14SEP09]
Aradigm
to Present at the 8th Annual BIO Investor Forum on October 28
[22OCT09]
Aradigm
Presents Data Demonstrating Significant Antibacterial Concentrations
and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following
Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
[14SEP09]
Aradigm
Announces Second Quarter 2009 Financial Results
[06AUG09]
Aradigm
Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin
to Treat Cystic Fibrosis in Europe
[05AUG09]
Zogenix
Announces Exclusive Co-Promotion Agreement in U.S. for Sumavel(TM)
DosePro(TM)
[04AUG09]
Aradigm
Receives FDA Clearance for Phase IIb Clinical Trial of Inhaled Liposomal
Ciprofloxacin to Treat Bronchiectasis
[23JUL09]
Zogenix
Obtains Approval in U.S. for Sumavel(TM) DosePro(TM)
[16JUN09]
Upcoming Events
For a listing of Upcoming Events click
here.
|
News & Events